A TRIAL OF LOBAPLATIN (D-19466) IN PLATINUM-RESISTANT OVARIAN-CANCER


KAVANAGH J., EDWARDS C., FREEDMAN R., FINNEGAN M., BALAT O., TRESUKOSOL D., ...Daha Fazla

GYNECOLOGIC ONCOLOGY, cilt.58, ss.106-109, 1995 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 58 Konu: 1
  • Basım Tarihi: 1995
  • Doi Numarası: 10.1006/gyno.1995.1191
  • Dergi Adı: GYNECOLOGIC ONCOLOGY
  • Sayfa Sayıları: ss.106-109

Özet

Long-term survival in epithelial ovarian cancer remains problematic despite multimodality therapy, A fundamental difficulty is the development of tumor resistance to platinum compounds, Analogs have been developed that demonstrate activity in platinum-resistant cell lines both in vitro and in vivo. Lobaplatin (D-19466), a third-generation compound, demonstrates significant activity in carboplatin and cisplatin-resistant cell lines, Lobaplatin was given to 17 assessable patients with platinum-refractory ovarian cancer. The drug was initially administered at a dose of 50 mg/m(2) but was later reduced to 40 mg/m(2) because of excessive thrombocytopenia, Nine patients required red cell transfusions during therapy, Cycles were repeated every 21-35 days (median cycle length 28 days), No objective responses were observed, Lobaplatin has no activity in platinum-resistant epithelial ovarian cancer. (C) 1995 Academic Press, Inc.